Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells

Cancer Immunology, Immunotherapy

Volumn 60, Issue 7, 2011, Pages 1029-1038

  Kato, Masato ^a   Nakamura, Yutaro ^a   Suda, Takafumi ^a   Ozawa, Yuichi ^a   Inui, Naoki ^a   Seo, Naohiro ^a   Nagata, Toshi ^a   Koide, Yukio ^a   Kalinski, Pawel ^b   Nakamura, Hirotoshi ^a   Chida, Kingo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cancer vaccine; Cellular immunotherapy; Dendritic cell; Low dose cyclophosphamide; Superantigen

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 12P70; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; STAPHYLOCOCCUS ENTEROTOXIN A; STAPHYLOCOCCUS ENTEROTOXIN B; SUPERANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG POTENTIATION; IMMUNE RESPONSE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR VOLUME;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, LEWIS LUNG; CD8-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; CYTOKINES; DENDRITIC CELLS; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERFERON-GAMMA; INTERLEUKIN-12; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOMA; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OVALBUMIN; RECEPTORS, G-PROTEIN-COUPLED; SUPERANTIGENS; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR CELLS, CULTURED; VACCINES, SUBUNIT;

EID: 79959705708     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1015-5     Document Type: Article

References (38)

1. J White A Herman AM Pullen, et al. 1989 The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal depetion in neonatal mice Cell 56 27 35 2521300 10.1016/0092-8674(89)90980-X 1:CAS:528:DyaL1MXptlWkug%3D%3D (Pubitemid 19033513)
2. H Li A Liera D Tsuchiya, et al. 1998 Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B Immunity 9 807 816 9881971 10.1016/S1074-7613(00)80646-9 1:CAS:528:DyaK1MXms1CksQ%3D%3D (Pubitemid 29024460)
3. EL Malchiodi E Eisenstein BA Fields, et al. 1995 Superantigen binding to a T cell receptor betachain of known three-dimensional structure J Exp Med 182 1833 1845 7500029 10.1084/jem.182.6.1833 1:CAS:528:DyaK2MXpslymur4%3D
4. EJ Sundberg H Li AS Liera, et al. 2002 Structures of two streptococcal superantigens bound to TCR beta chains reveal diversity in the architecture of T cell signaling complexs Structure 10 687 699 12015151 10.1016/S0969-2126(02) 00759-1 1:CAS:528:DC%2BD38XjvVWjtLc%3D (Pubitemid 34520468)
5. BL Kotzin DYM Leung J Kappler P Marrack 1993 Superantigen and their potential role in human disease Adv Immunol 54 99 166 8397479 10.1016/S0065-2776(08)60534-9 1:CAS:528:DyaK3sXms1yitb4%3D (Pubitemid 23289252)
6. SR Webb NRJ Gascoigne 1994 T-cell activation by superantigens Curr Opin Immunol 6 467 475 7917116 10.1016/0952-7915(94)90129-5 1:CAS:528: DyaK2cXltlWksrk%3D (Pubitemid 24188499)
7. MJ Litton B Sander E Murphy, et al. 1994 Early expression of cytokines in lymph nodes after treatment in vivo with Staphylococcus enterotoxin B J Immunol Methods 175 47 58 7930639 10.1016/0022-1759(94)90330-1 1:CAS:528: DyaK2cXmsFent7w%3D (Pubitemid 24305230)
8. Y Kawabe A Ochi 1991 Programmed cell death and extrathymic reduction of V beta8+ CD4+ T cells in mice tolerant to Staphylococcal aureus enterotoxin B Nature 349 245 248 1670963 10.1038/349245a0 1:CAS:528:DyaK3MXhtF2rsbo%3D (Pubitemid 21912057)
9. K Heeg H Gaus D Griese S Bendig T Miethke H Wagner 1995 Superantigen-reactive T cells that display an anergic phenotype in vivo appear functional in vivo Int Immunol 7 105 114 7718507 10.1093/intimm/7.1.105 1:CAS:528:DyaK2MXktlWnurg%3D
10. A Sundstedt M Dohlsten G Hedlund I Hoiden M Bjorklund T Kalland 1994 Superantigens anergize cytokine production but not cytotoxity in vivo Immunology 82 117 125 7913912 1:CAS:528:DyaK2cXkvVSmsro%3D (Pubitemid 24234548)
11. N Bhardwaj SM Fried man BC Cole AJ Nisanian 1992 Cendritic cells are potent antigen-presenting cells for microbial superantigens J Exp Med 175 267 273 1730919 10.1084/jem.175.1.267 1:CAS:528:DyaK38Xls12htA%3D%3D
12. N Bhrardwaj JW Young AJ Nisanian J Baggers RM Steinman 1993 Small amounts of superantigens, when presented on dendritic cells, are sufficient to initiatiate to T cellresponses J Exp Med 178 633 642 10.1084/jem.178.2.633 (Pubitemid 23218212)
13. S Gurunathan L Stobie C Prussin, et al. 2001 Requirements for the maintenance of Th1 immunity in vivo following DNAvaccination: A potential immunoregulatory role for CD8+ T cells J Immunol 16 1283 1289
14. B Wang CC Norbury R Greenwood JR Bonnink Jw Yewdell JA Frelinger 2001 Multiple paths for activation of naïve CD8+ T cells: CD4-independent help J Immunol 167 1283 1289 11466344 1:CAS:528:DC%2BD3MXls1Wkur8%3D (Pubitemid 32703123)
15. RB Mailliard S Egawa Q Cai, et al. 2002 Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses J Exp Med 195 473 483 11854360 10.1084/jem.20011662 1:CAS:528:DC%2BD38XhslOrt7s%3D (Pubitemid 34461300)
16. Y Nakamura P Watchmaker J Urban, et al. 2007 Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity Cancer Res 67 10012 10018 17942935 10.1158/0008-5472.CAN-07-1735 1:CAS:528:DC%2BD2sXhtFOnsLrK (Pubitemid 47621252)
17. T Osada TM Clay CY Woo MA Morse HK Lyerly 2006 Dendritic cell-based immunotherapy Int Rev Immunol 25 377 413 17169781 10.1080/08830180600992456 1:CAS:528:DC%2BD2sXisl2luw%3D%3D (Pubitemid 44972272)
18. SMF Fazle Akbar M Abe O Yoshida H Murakami M Onji 2006 Dendritic cell-based therapy as a multidisciplinary approach to cancer treatment: present limitations and future scopes Curr Med Chem 13 3113 3119 17168700 10.2174/092986706778742882 1:STN:280:DC%2BD28jjtFersA%3D%3D (Pubitemid 44680858)
19. MEC Lutsiak RT Semnani RD Pascalis SVS Kashmiri J Schlom H Sabzevari 2005 Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 105 2862 2868 15591121 10.1182/blood-2004-06-2410 1:CAS:528:DC%2BD2MXivFGmtLw%3D (Pubitemid 40446280)
20. T Ito N Seo H Yagi K Tsujimura M Takigawa Y Tokura 2003 Alterations of immune functions in barrier disrupted skin by UVB irradiation J Dermatol Sci 33 151 159 14643520 10.1016/S0923-1811(03)00177-4 1:CAS:528:DC%2BD3sXpt1WhsLw%3D (Pubitemid 37485696)
21. Y Nakamura T Suda T Nagata, et al. 2003 Induction of protective immunity to Listeria monocytogenes with dendritic cells retrovirally transduced with a cytotoxic T lymphocyte epitope minigene Infect Immun 71 1748 1754 12654788 10.1128/IAI.71.4.1748-1754.2003 1:CAS:528:DC%2BD3sXislOhsrk%3D (Pubitemid 36368703)
22. N Enomoto T Nagata T Suda, et al. 2007 Immunization with dendritic cells loaded with alpha-galactosylceramide at priming phase, but not at boosting phase, enhances cytotoxic T lymphocyte activity against infection by intracellular bacteria FEMS Immunol Med Microbiol 51 350 362 17760876 10.1111/j.1574-695X.2007.00316.x 1:CAS:528:DC%2BD2sXht1aisLvE (Pubitemid 47547514)
23. Y Ozawa T Suda T Nagata, et al. 2009 Mucosal vaccine using CTL epitope-pulsed dendritic cells confers protection for intracellular pathogen Am J Respir Cell Mol Biol 41 440 448 19202004 10.1165/rcmb.2008-0446OC 1:CAS:528:DC%2BD1MXht1Squ7fP
24. SL Kominsky BA Torres AC Hobeika FA Lake HM Johnson 2001 Superantigen enhanced protection against a weak tumor-specific melanoma antigen: implications for prophylactic vaccination against cancer Int J Cancer 94 834 841 11745486 10.1002/ijc.1551 1:CAS:528:DC%2BD3MXotFOku74%3D (Pubitemid 33032832)
25. E Muraille DC Trez B Pajak M Brait J Urbain O Leo 2002 T cell-dependent maturation of dendritic cells in response to bacterial superantigens J Immunol 168 4352 4360 11970977 1:CAS:528:DC%2BD38Xjt12jsbs%3D (Pubitemid 34441335)
26. CE Egwu W Li C-R Yu, et al. 2006 Interferone-γ induce regression of epithelial cell carcinoma: critical role of IRF-1 and ICSBP transcription factors Oncogene 25 3670 3679 10.1038/sj.onc.1209402 (Pubitemid 43980488)
27. M Kortylewski W Komyod M-E Kauffmann, et al. 2004 Interferone-γ- mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals J Invest Dermatol 122 414 422 15009724 10.1046/j.0022-202X.2004.22237.x 1:CAS:528:DC%2BD2cXitlGiurg%3D (Pubitemid 38281063)
28. XZ He L Wang YY Zhang 2008 An effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cells World J Gastroenterol 14 532 540 18203284 10.3748/wjg.14.532 1:CAS:528:DC%2BD1cXjvFKksb4%3D (Pubitemid 351320818)
29. H Iinuma K Okinaga R Fukushima, et al. 2006 Superior protective and therapeutic effect of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma J Immunol 176 3461 3469 16517714 1:CAS:528:DC%2BD28XitVSkt7c%3D (Pubitemid 43363993)
30. CH Kim MJ Hong SD Park, et al. 2006 Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12 Cancer Immunol Immunother 55 1309 1319 16463038 10.1007/s00262-006-0134-x 1:CAS:528:DC%2BD28Xnsl2jtbs%3D (Pubitemid 44187662)
31. N Matsushita AP-T Shari LM Martin AI Riker 2008 Comparative methodologies of regulatory T cell depletion in a murine melanoma model J Immunol Methods 333 167 179 18295790 10.1016/j.jim.2008.01.012 1:CAS:528:DC%2BD1cXktlWrsr8%3D
32. B Valzasina S Piconese C Guiducci MP Colombo 2006 Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent Cancer Res 66 4488 4495 16618776 10.1158/0008-5472. CAN-05-4217 1:CAS:528:DC%2BD28XjsFSlu7w%3D
33. G Zhou GC Drake IH Levitsky 2006 Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines Blood 107 628 636 16179369 10.1182/blood-2005-07-2737 1:CAS:528:DC%2BD28Xms1ektw%3D%3D (Pubitemid 43076387)
34. JY Liu Y Wu XS Zhang, et al. 2007 Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine Cancer Immunol Immunother 56 1597 1604 17440723 10.1007/s00262-007-0305-4 1:CAS:528:DC%2BD2sXotVKktr0%3D (Pubitemid 47094389)
35. S Wirth F Bille S Koenig, et al. 2002 Testing mouse mammary virus superantigen as adjuvant in cytotoxic T-lymphcyte responses against a melanoma tumor antigen Int J Cancer 99 201 206 11979434 10.1002/ijc.10237 1:CAS:528:DC%2BD38XivFyrsrg%3D (Pubitemid 34309476)
36. JD Cheng JS Babb C Langer, et al. 2004 Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936 J Clin Oncol 22 602 609 14966084 10.1200/JCO.2004.12.034 1:CAS:528:DC%2BD2cXpsVajs7o%3D (Pubitemid 41095062)
37. Xiu Fangming Z Cai Y Yang X Wang J Wang X Cao 2007 Surface anchorage of superantigen SEA promotes induction of specific antitumor immune response by tumor-derived exosomes J Mol Med 85 511 521 10.1007/s00109-006-0154-1 (Pubitemid 46701660)
38. S Ren DS Terman G Bohach, et al. 2004 Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and and a survival benefit in non-small cell lung cancer Chest 125 1529 1539 10.1378/chest.126.5.1529 (Pubitemid 39525027)